Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Income Statement
12 months ended: | Revenues | Net income attributable to Pfizer Inc. |
---|---|---|
Dec 31, 2024 | ||
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
- Revenues
-
Revenues exhibited a fluctuating pattern over the analyzed period. The values remained relatively stable around the 48,000 to 51,000 million US dollars mark from 2005 through 2009, with a noticeable jump in 2010 reaching approximately 67,809 million US dollars. Following this peak, revenues experienced a decline and volatility, decreasing steadily from 2011 to 2014. A gradual recovery occurred from 2015 to 2019, with revenues nearing earlier highs but not surpassing the 2010 peak. A significant drop was recorded in 2020, coinciding with the COVID-19 pandemic period, falling to around 42,678 million US dollars. This was followed by a rapid increase in 2021 and 2022, reaching the highest point in the entire dataset at about 101,175 million US dollars. However, revenues sharply declined again in 2023 and showed a slight recovery in 2024 but remained below the 2022 peak.
- Net income attributable to Pfizer Inc.
-
Net income presented substantial variability across the years. The initial years from 2005 to 2007 show moderate values fluctuating between approximately 6,960 and 8,144 million US dollars. A notable surge occurred in 2006 with net income over 19,000 million US dollars, which is an outlier compared to adjacent years. From 2008 to 2010, net income values stabilized within an 8,000 to 10,000 million US dollars range. The period from 2011 brought sustained growth in net income, peaking at around 22,003 million US dollars in 2013 and reaching a new high of approximately 21,308 million in 2017. Another peak occurred in 2022 with net income rising to approximately 31,372 million US dollars, correlating with the highest revenue year. In contrast, 2023 experienced a sharp decline in net income to about 2,119 million US dollars, followed by partial recovery in 2024, still falling short of previous high levels.
- Overall Trends and Insights
-
The revenue and net income trends reveal a pattern of volatility and strong cyclical behavior, likely influenced by external market conditions and internal company events. The substantial increases in both revenues and net income around 2021-2022 suggest a period of exceptional performance or successful product launches. Conversely, significant drops in 2020 and 2023 indicate vulnerability to adverse conditions or extraordinary expenses. The net income is more volatile than revenues, indicating fluctuations in profitability margins and operational efficiency. The alignment of peaks in revenues and net income in the latter years of the dataset suggests periods of effective cost management and business expansion.
Balance Sheet: Assets
Current assets | Total assets | |
---|---|---|
Dec 31, 2024 | ||
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Analysis of the financial data reveals notable trends in both current assets and total assets over the period.
- Current Assets
- The current assets exhibit fluctuations throughout the years. Beginning at approximately $41.9 billion in 2005, the value generally increased until reaching a peak near $61.7 billion in 2009. Following 2009, current assets showed volatility with declines and recoveries, including a significant drop to about $32.8 billion in 2019. Subsequently, there was a recovery trend through 2024, rising again to around $50.4 billion.
- Total Assets
- The total assets also display variability but on a larger scale. Starting at about $117.6 billion in 2005, total assets decreased slightly to near $111.1 billion by 2008 before experiencing a major increase to $212.9 billion in 2009. After this peak, there was a gradual decline and stabilization through the early 2010s, falling to a trough of approximately $154.2 billion in 2020. From 2020 onward, total assets increased steadily, reaching approximately $213.4 billion by 2024.
Overall, both current and total assets show patterns of growth interspersed with periods of contraction. The significant increases around 2009 suggest potential acquisition activity or asset revaluation during that period. The fluctuations in current assets in more recent years may reflect changes in working capital management or liquidity positions. The recovery and growth in total assets after 2020 indicate strengthening asset base or investment expansions heading into 2024.
Balance Sheet: Liabilities and Stockholders’ Equity
Pfizer Inc., selected items from liabilities and stockholders’ equity, long-term trends
US$ in millions
Current liabilities | Total liabilities | Total debt | Total Pfizer Inc. shareholders’ equity | |
---|---|---|---|---|
Dec 31, 2024 | ||||
Dec 31, 2023 | ||||
Dec 31, 2022 | ||||
Dec 31, 2021 | ||||
Dec 31, 2020 | ||||
Dec 31, 2019 | ||||
Dec 31, 2018 | ||||
Dec 31, 2017 | ||||
Dec 31, 2016 | ||||
Dec 31, 2015 | ||||
Dec 31, 2014 | ||||
Dec 31, 2013 | ||||
Dec 31, 2012 | ||||
Dec 31, 2011 | ||||
Dec 31, 2010 | ||||
Dec 31, 2009 | ||||
Dec 31, 2008 | ||||
Dec 31, 2007 | ||||
Dec 31, 2006 | ||||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
The analysis of the provided financial data reveals several noteworthy trends in the company’s liabilities, debt, and shareholders’ equity over the period spanning from 2005 to 2024.
- Current Liabilities
- Current liabilities showed fluctuations across the years. Starting at $28,448 million in 2005, there was a dip in 2006 to $21,389 million, followed by a general increasing trend reaching a peak of $47,794 million in 2023. The year 2009 exhibited a significant spike at $37,225 million, likely indicating increased short-term obligations during that period. Despite some volatility, the upward trend in recent years suggests growing short-term liabilities.
- Total Liabilities
- Total liabilities increased sharply from $51,938 million in 2005 to a substantial $122,503 million in 2009, marking the most significant escalation within the dataset. Post-2009, total liabilities generally stabilized, fluctuating around the $95,000 million to $111,000 million range until 2021. From 2022 onward, there was a noticeable rise, peaking at approximately $137,213 million in 2023 before slightly declining to $124,899 million in 2024. This pattern suggests a major expansion phase around 2009 followed by a period of relative stability and recent growth.
- Total Debt
- Total debt experienced considerable variation over the years. Initial levels were $17,936 million in 2005, decreasing sharply to $7,980 million in 2006, followed by a general upward movement that peaked at $52,150 million in 2019. Notably, 2023 shows another peak at $71,888 million, the highest in the dataset, before a slight decrease in 2024 to $64,351 million. The increasing debt levels in recent years may reflect additional financing or capital structuring activities. The volatility in earlier years denotes changing leverage strategies or possibly impacts from corporate actions or market conditions.
- Shareholders’ Equity
- Shareholders’ equity showed mixed trends. Starting at $65,627 million in 2005, equity peaked at $71,358 million in 2006, then trended downward, reaching a low of $59,544 million in 2016. Following this, the equity value rebounded strongly, peaking at $95,661 million in 2021, indicative of improved retained earnings or capital increases. However, equity declined thereafter to about $88,203 million by 2024. This fluctuation suggests periods of both value erosion and enhancement, possibly influenced by earnings performance, dividends, share repurchases, or other equity-related activities.
In summary, the company exhibited significant shifts in both liabilities and equity over the period. The rise in total liabilities and debt, especially post-2008 and peaking around 2019 and 2023, highlights increased leverage. Meanwhile, shareholders’ equity showed recovery after mid-period declines, suggesting resilience in net asset value despite heavier financing. The recent trends imply a strategic phase of capital restructuring or expansion coupled with fluctuating equity values that warrant further examination of the underlying operational and financial decisions.
Cash Flow Statement
12 months ended: | Net cash provided by operating activities | Net cash (used in) provided by investing activities | Net cash provided by (used in) financing activities |
---|---|---|---|
Dec 31, 2024 | |||
Dec 31, 2023 | |||
Dec 31, 2022 | |||
Dec 31, 2021 | |||
Dec 31, 2020 | |||
Dec 31, 2019 | |||
Dec 31, 2018 | |||
Dec 31, 2017 | |||
Dec 31, 2016 | |||
Dec 31, 2015 | |||
Dec 31, 2014 | |||
Dec 31, 2013 | |||
Dec 31, 2012 | |||
Dec 31, 2011 | |||
Dec 31, 2010 | |||
Dec 31, 2009 | |||
Dec 31, 2008 | |||
Dec 31, 2007 | |||
Dec 31, 2006 | |||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
- Net cash provided by operating activities
- The net cash provided by operating activities demonstrates significant fluctuation over the periods observed. Starting at $14,733 million in 2005, the value increased markedly to reach a peak of $20,240 million in 2011. Following this, the figures generally declined with intermittent recovery years, such as 2016 and 2017 where values hovered around $16,000 million. A substantial decline is noted in 2019 and 2020, reaching lows of $12,588 million and $10,586 million respectively. However, there was a remarkable surge in 2021, with net cash flow increasing sharply to $32,922 million, followed by a slight reduction but still elevated level in 2022 at $29,267 million. The latest years, 2023 and 2024, show a reduction to $8,700 million and $12,744 million respectively, indicating recent volatility.
- Net cash (used in) provided by investing activities
- Investing activities reveal a largely negative trend with significant cash outflows in several periods. A positive inflow was observed in 2006 and 2007, with $5,101 million and $795 million respectively, and again in 2012 at $6,154 million and 2018 at $4,525 million. These were exceptions in a generally negative investment cash flow scenario. The largest outflows occurred in 2009 (-$31,272 million), 2013 (-$10,625 million), 2022 (-$15,783 million), and especially 2023 with a sharp outflow of -$32,278 million. Some periods, such as 2024, indicate a positive inflow of $2,652 million. The data suggest aggressive investing activities particularly in some years, possibly linked to acquisitions or capital expenditures.
- Net cash provided by (used in) financing activities
- Financing activities generally show negative cash flow across most years, indicating net cash usage. The largest outflows were recorded in 2006 (-$23,100 million), 2011 (-$20,607 million), 2018 (-$20,441 million), and 2020 (-$21,640 million). Positive inflows were recorded in 2009 ($14,481 million) and notably in 2023 with a significant inflow of $26,066 million. This irregular inflow suggests financing events such as equity or debt issuance. Overall, cash used in financing activities has been substantial and consistent, except for isolated years that reflect capital raising or refinancing activities.
Per Share Data
12 months ended: | Basic earnings per share 1 | Diluted earnings per share 2 | Dividend per share 3 |
---|---|---|---|
Dec 31, 2024 | |||
Dec 31, 2023 | |||
Dec 31, 2022 | |||
Dec 31, 2021 | |||
Dec 31, 2020 | |||
Dec 31, 2019 | |||
Dec 31, 2018 | |||
Dec 31, 2017 | |||
Dec 31, 2016 | |||
Dec 31, 2015 | |||
Dec 31, 2014 | |||
Dec 31, 2013 | |||
Dec 31, 2012 | |||
Dec 31, 2011 | |||
Dec 31, 2010 | |||
Dec 31, 2009 | |||
Dec 31, 2008 | |||
Dec 31, 2007 | |||
Dec 31, 2006 | |||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1, 2, 3 Data adjusted for splits and stock dividends.
- Earnings per Share (Basic and Diluted)
- Over the examined period, basic earnings per share (EPS) demonstrate considerable volatility with multiple peaks and troughs. Initially, EPS increased sharply from 1.1 US$ in 2005 to a peak of 2.67 US$ in 2006, then decreased to values near 1.1 to 1.2 US$ in the subsequent years until 2010. A notable upward trend occurred from 2012, reaching a significant peak around 3.57 US$ in 2017, followed by further fluctuations including a high of 5.59 US$ in 2022 and an abrupt decline to 0.38 US$ in 2023 before a partial recovery to 1.42 US$ in 2024.
- The diluted EPS closely follows the trend of basic EPS but is marginally lower throughout the timeframe, which is consistent with typical dilution effects.
- Dividend per Share
- The dividend per share shows a steady and consistent upward trajectory throughout the period under review. Starting at 0.76 US$ in 2005, it gradually rises each year with minor variation, reaching 1.69 US$ by 2024. This indicates a stable policy of increasing shareholder returns via dividends despite fluctuations in earnings.
- Trend Interpretation
- The earnings per share figures indicate a business subject to significant operational or market volatility, as evidenced by large swings particularly between 2016 and 2024. The sharp fall in EPS in 2023 is notable and may suggest a one-time event or financial stress impacting profitability. However, the dividend per share growth remains consistent, reflecting a commitment to maintaining and increasing dividends over time, which could be aimed at signaling financial health and stability to investors despite short-term earnings variability.
- Overall, the data reflects a dynamic earnings environment coupled with a disciplined dividend growth approach.